Immunomodulating Agents – Talk Bio

Actionable Insights Powered by AI

Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio

5 months ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, Immunomodulating Agents, Nuvig, NVG-2089, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Series B financing

Nuvig Therapeutics, Series B financing, immunomodulatory drugs, autoimmune diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), NVG-2089, clinical trials.